このエントリーをはてなブックマークに追加
ID 32866
JaLCDOI
FullText URL
Author
Fujimoto, Nobukazu
Takigawa, Nagio
Fujiwara, Yoshiro
Toyooka, Shinichi
Umemura, Shigeki
Tabata, Masahiro Kaken ID researchmap
Ueoka, Hiroshi
Abstract

We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were <70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.

Keywords
cisplatin
docetaxel
irinotecan
triplet chemotherapy
gefitinib
Amo Type
Original Article
Published Date
2010-02
Publication Title
Acta Medica Okayama
Volume
volume64
Issue
issue1
Publisher
Okayama University Medical School
Start Page
33
End Page
37
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT